The estimated Net Worth of James T. Gunton is at least $746 mil dollars as of 14 October 2014. James Gunton owns over 143,787 units of Cytosorbents Corp stock worth over $2 and over the last 12 years James sold CTSO stock worth over $745,677.
James has made over 7 trades of the Cytosorbents Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently James sold 143,787 units of CTSO stock worth $34,509 on 14 October 2014.
The largest trade James's ever made was selling 1,360,000 units of Cytosorbents Corp stock on 26 August 2014 worth over $326,400. On average, James trades about 282,453 units every 4 days since 2013. As of 14 October 2014 James still owns at least 2 units of Cytosorbents Corp stock.
You can see the complete history of James Gunton stock trades at the bottom of the page.
James's mailing address filed with the SEC is 7 DEER PARK DRIVE, SUITE K, , MONMOUTH JUNCTION, NJ, 08852.
Over the last 16 years, insiders at Cytosorbents Corp have traded over $1,216,453 worth of Cytosorbents Corp stock and bought 832,447 units worth $1,058,402 . The most active insiders traders include James T. Gunton, Al Kraus, ePhillip P. Chan. On average, Cytosorbents Corp executives and independent directors trade stock every 34 days with the average trade being worth of $41,883. The most recent stock trade was executed by Alan D. Sobel on 13 December 2023, trading 22,557 units of CTSO stock currently worth $30,001.
cytosorbents (nasdaq: ctso) cytosorbents corporation is a leader in critical care immunotherapy, specializing in blood purification. its flagship product, cytosorb® is approved in the european union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. these are conditions where the risk of death is extremely high, yet no effective treatments exist. cytosorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. cytosorbents' purification technologies are based on biocompatible, highly porous polymer beads
Cytosorbents Corp executives and other stock owners filed with the SEC include: